Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

CapsoVision, Inc (CV) Financial Statements

CapsoVision, Inc (CV) reported trailing twelve-month revenue of $13.9M (up 11.0% year on year) and net income of -$29.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$27.9M.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

CVCapsoVision, IncFollow CV — free
Medical Devices · Healthcare
—
Price chart with a free account
Market cap
349.8M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
12 Nov, in 19 days

Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.

LineFY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Revenue11.813.613.9
Gross profit6.47.27.1
Research & development15.118.321.6
Operating income-19.9-25.5-30.2
Pre-tax income-19.9-25.3-29.8
Income tax0.00.00.0
Net income-19.9-25.3-29.8
Diluted EPS ($)-9.85-1.03-0.60
Diluted shares (mn)2.024.6—

USD millions · SEC XBRL

CapsoVision, Inc — questions

What is CapsoVision, Inc's revenue?
$13.9M over the twelve months to 2026-06-30, up 11.0% year on year, from its 10-Q and 10-K filings.
What is CapsoVision, Inc's net income?
-$29.8M over the twelve months to 2026-06-30.
What is CapsoVision, Inc's free cash flow?
-$27.9M over the twelve months to 2026-06-30.
What are CapsoVision, Inc's diluted earnings per share?
$-0.60 over the twelve months to 2026-06-30.

Every figure on this page comes from CapsoVision, Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.